Overview

NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis

Status:
Recruiting
Trial end date:
2024-05-30
Target enrollment:
Participant gender:
Summary
This research study involves studying a device as a possible treatment for metastatic melanoma in the brain. The purpose of this study is to obtain information on the safety and effectiveness of the study device, NovoTTF-200A, in melanoma participants with brain metastases when it is combined with Pembrolizumab. The name of the study device involved in this study is: -- NovoTTF-200A The name of the drug used in this study is: -- Pembrolizumab
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Eric Wong, MD
Treatments:
Pembrolizumab